18060

543960

CONCORDBIO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

CONCORD BIOTECH LIMITED Share Price Today

CONCORD BIOTECH LIMITED is currently trading at ₹1353.8, up by ₹10.5 from the previous close. The stock touched an intraday high of ₹1367.40 and a low of ₹1335.60 during the latest trading session. Over the past one year, CONCORD BIOTECH LIMITED has delivered a loss of 34.39%, while the stock has gained 20.1% in the last one month.

CONCORD BIOTECH LIMITED performance

Today’s low Today’s high
₹ 1335.60 ₹ 1367.40
₹ 1353.80
52 week low 52 week high
₹ 987.00 ₹ 2146.00
₹ 1353.80
Open Price ₹ 1345.10
Prev. Close ₹ 1343.30
Volume (Shares) 358864.00
Total traded value ₹ 4858.30
Upper Circuit ₹ 1611.90
Lower Circuit ₹ 1074.70
info

Investment Returns

Over 1 Month 20.10% Over 3 Months 15.26% Over 6 Months -1.16% Over 1 Year -34.39%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

CONCORD BIOTECH LIMITED fundamentals


  • Market cap (Cr) 14,162.90
  • P/E Ratio (TTM) 53.79
  • Beta 0.82
  • Book Value / share 193.06
  • Return on equity 22.35%
  • EPS (TTM) 25.40
  • Dividend yield 0.56%
  • Net profit/quarter (Cr) 90.02
info icon alternate text
  • Market cap (Cr) 14,163.50
  • P/E Ratio (TTM) 53.79
  • Beta 0.70
  • Book Value / share 193.06
  • Return on equity 22.35%
  • EPS (TTM) 25.40
  • Dividend yield 0.56%
  • Net profit/quarter (Cr) 90.02
info icon alternate text

CONCORD BIOTECH LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 325.89
Operating Expense 223.06
Net Profit 90.02
Net Profit Margin (%) 27.62
Earnings Per Share (EPS) 8.60
EBITDA 137.93
Effective Tax Rate (%) 23.95
Particulars DEC 2025 (Values in Cr)
Revenue 278.13
Operating Expense 194.65
Net Profit 67.78
Net Profit Margin (%) 24.36
Earnings Per Share (EPS) 6.48
EBITDA 109.03
Effective Tax Rate (%) 24.92
Particulars SEP 2025 (Values in Cr)
Revenue 247.06
Operating Expense 174.97
Net Profit 62.90
Net Profit Margin (%) 25.45
Earnings Per Share (EPS) 6.01
EBITDA 103.97
Effective Tax Rate (%) 26.44
Particulars JUN 2025 (Values in Cr)
Revenue 203.99
Operating Expense 160.43
Net Profit 42.57
Net Profit Margin (%) 20.86
Earnings Per Share (EPS) 4.07
EBITDA 75.08
Effective Tax Rate (%) 25.62
Particulars MAR 2025 (Values in Cr)
Revenue 429.88
Operating Expense 254.18
Net Profit 141.94
Net Profit Margin (%) 33.01
Earnings Per Share (EPS) 13.57
EBITDA 199.81
Effective Tax Rate (%) 23.31
Particulars MAR 2026 (Values in Cr)
Revenue 1055.07
Operating Expense 753.09
Net Profit 263.27
Net Profit Margin (%) 24.95
Earnings Per Share (EPS) 25.17
EBITDA 425.99
Effective Tax Rate (%) 25.08
Particulars MAR 2025 (Values in Cr)
Revenue 1200.09
Operating Expense 748.66
Net Profit 372.96
Net Profit Margin (%) 31.07
Earnings Per Share (EPS) 35.65
EBITDA 550.78
Effective Tax Rate (%) 24.78
Particulars MAR 2024 (Values in Cr)
Revenue 1016.94
Operating Expense 641.52
Net Profit 304.73
Net Profit Margin (%) 29.96
Earnings Per Share (EPS) 29.13
EBITDA 465.33
Effective Tax Rate (%) 25.52
Particulars MAR 2023 (Values in Cr)
Revenue 853.17
Operating Expense 568.42
Net Profit 238.13
Net Profit Margin (%) 27.91
Earnings Per Share (EPS) 22.76
EBITDA 378.59
Effective Tax Rate (%) 25.59
Particulars MAR 2022 (Values in Cr)
Revenue 712.93
Operating Expense 495.19
Net Profit 178.57
Net Profit Margin (%) 25.04
Earnings Per Share (EPS) 187.76
EBITDA 296.69
Effective Tax Rate (%) 25.95
Particulars MAR 2025 (Values in Cr)
Book Value / Share 173.27
ROE % 22.26
ROCE % 29.53
Total Debt to Total Equity 0.00
EBITDA Margin 45.83
Particulars MAR 2024 (Values in Cr)
Book Value / Share 145.93
ROE % 21.88
ROCE % 29.05
Total Debt to Total Equity 0.01
EBITDA Margin 46.15
Particulars MAR 2023 (Values in Cr)
Book Value / Share 123.31
ROE % 20.06
ROCE % 26.27
Total Debt to Total Equity 0.04
EBITDA Margin 44.68
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1159.99
ROE % 16.64
ROCE % 21.59
Total Debt to Total Equity 0.07
EBITDA Margin 41.20
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1050.80
ROE % 26.60
ROCE % 32.83
Total Debt to Total Equity 0.08
EBITDA Margin 55.42
Particulars MAR 2025 (Values in Cr)
Book Value / Share 173.27
ROE % 22.35
ROCE % 29.62
Total Debt to Total Equity 0.00
EBITDA Margin 45.94
Particulars MAR 2024 (Values in Cr)
Book Value / Share 145.80
ROE % 21.63
ROCE % 28.81
Total Debt to Total Equity 0.01
EBITDA Margin 45.82
Particulars MAR 2023 (Values in Cr)
Book Value / Share 123.50
ROE % 19.85
ROCE % 26.05
Total Debt to Total Equity 0.04
EBITDA Margin 44.45
Particulars MAR 2022 (Values in Cr)
Book Value / Share 1164.13
ROE % 16.95
ROCE % 21.86
Total Debt to Total Equity 0.07
EBITDA Margin 41.71
Particulars MAR 2021 (Values in Cr)
Book Value / Share 1051.11
ROE % 26.59
ROCE % 32.82
Total Debt to Total Equity 0.08
EBITDA Margin 55.39
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.18
Total Assets 2034.25
Total Liabilities 2034.25
Total Equity 1812.71
Share Outstanding 10
Price to Book Ratio 9.67
Return on Assets (%) 18.26
Return on Capital (%) 20.5
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 47.02
Total Assets 1700.70
Total Liabilities 1700.70
Total Equity 1526.64
Share Outstanding 10
Price to Book Ratio 10.44
Return on Assets (%) 18.11
Return on Capital (%) 20.1
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 43.44
Total Assets 1513.98
Total Liabilities 1513.98
Total Equity 1290.00
Share Outstanding 10
Price to Book Ratio 0.00
Return on Assets (%) 15.85
Return on Capital (%) 18.17
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 88.93
Total Assets 1312.79
Total Liabilities 1312.79
Total Equity 1103.22
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 13.32
Return on Capital (%) 15.03
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 60.81
Total Assets 1182.54
Total Liabilities 1182.54
Total Equity 999.37
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 19.90
Return on Capital (%) 22.19
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.18
Total Assets 2034.18
Total Liabilities 2034.18
Total Equity 1812.64
Share Outstanding 10
Price to Book Ratio 9.67
Return on Assets (%) 18.33
Return on Capital (%) 20.57
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 47.02
Total Assets 1699.31
Total Liabilities 1699.31
Total Equity 1525.25
Share Outstanding 10
Price to Book Ratio 10.44
Return on Assets (%) 17.93
Return on Capital (%) 19.9
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 43.44
Total Assets 1514.64
Total Liabilities 1514.64
Total Equity 1291.98
Share Outstanding 10
Price to Book Ratio 0.00
Return on Assets (%) 15.72
Return on Capital (%) 18
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 88.93
Total Assets 1313.45
Total Liabilities 1313.45
Total Equity 1107.16
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 13.59
Return on Capital (%) 15.29
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 60.81
Total Assets 1182.84
Total Liabilities 1182.84
Total Equity 999.67
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 19.89
Return on Capital (%) 21.67
Particulars MAR 2025 (Values in Cr)
Net Income 494.55
Cash from Operations 353.93
Cash from Investing -159.98
Cash from Financing -98.76
Net change in Cash -14.23
Free Cash Flow 465.10
Particulars MAR 2024 (Values in Cr)
Net Income 412.56
Cash from Operations 368.81
Cash from Investing -154.60
Cash from Financing -99.21
Net change in Cash 11.64
Free Cash Flow 454.50
Particulars MAR 2023 (Values in Cr)
Net Income 322.01
Cash from Operations 316.27
Cash from Investing -157.95
Cash from Financing -85.21
Net change in Cash 2.83
Free Cash Flow 461.36
Particulars MAR 2022 (Values in Cr)
Net Income 237.51
Cash from Operations 268.25
Cash from Investing -111.78
Cash from Financing -100.16
Net change in Cash -4.47
Free Cash Flow 423.76
Particulars MAR 2020 (Values in Cr)
Net Income 213.63
Cash from Operations 204.19
Cash from Investing -113.92
Cash from Financing -42.51
Net change in Cash -1.35
Free Cash Flow 204.19
Particulars MAR 2025 (Values in Cr)
Net Income 495.87
Cash from Operations 353.93
Cash from Investing -159.98
Cash from Financing -98.76
Net change in Cash -14.23
Free Cash Flow 465.10
Particulars MAR 2024 (Values in Cr)
Net Income 409.19
Cash from Operations 368.81
Cash from Investing -154.60
Cash from Financing -99.21
Net change in Cash 11.64
Free Cash Flow 454.50
Particulars MAR 2023 (Values in Cr)
Net Income 320.05
Cash from Operations 316.27
Cash from Investing -157.95
Cash from Financing -85.21
Net change in Cash 2.83
Free Cash Flow 461.36
Particulars MAR 2022 (Values in Cr)
Net Income 241.15
Cash from Operations 268.25
Cash from Investing -111.78
Cash from Financing -100.16
Net change in Cash -4.47
Free Cash Flow 423.76
Particulars MAR 2021 (Values in Cr)
Net Income 313.16
Cash from Operations 241.98
Cash from Investing -195.20
Cash from Financing 31.12
Net change in Cash 2.73
Free Cash Flow 446.16
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 13.39 1.56 248.29 23.12 38.85
BLISS GVS PHARMA LTD. 438.10 35.56 3.89 4646.32 118.35 462.70
CIPLA LTD. 1388.80 29.47 3.25 112193.56 1165.55 1672.20
FERMENTA BIOTECH LTD. 338.80 14.94 2.45 997.12 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 22.66 4.17 248.29 23.12 38.85
AMRUTAJAN HEALTH LTD 557.75 25.00 4.35 1612.49 490.00 789.95
ASTRAZENECA PHARMA IND LT 8243.90 107.66 23.61 20609.75 7630.00 10653.05
BLISS GVS PHARMA LTD. 438.10 47.26 4.02 4646.32 118.35 462.70

CONCORD BIOTECH LIMITED shareholding pattern

Holding
38.9%
44.08%
7.79%
9.22%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

CONCORD BIOTECH LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
1353.80 0.78 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 1306.80
  • 26 Days 1192.80
  • 10 Days 1258.30
  • 50 Days 1166.90
  • 12 Days 1244.70
  • 100 Days 1194.80
  • 20 Days 1208.90
  • 200 Days 1310.00
1330.00 PIVOT
First Support 1311.00 First Resistance 1362.30 Second Support 1278.70 Second Resistance 1381.30 Third Support 1259.70 Third Resistance 1413.60
RSI 70.55 ADX 25.97 MACD 51.97 Williams % R -3.94 Commodity Channel Index (CCI) 167.41
Date 2026-06-12 Week 135445.00 Same Day 168194.00 Month 121058.00
1 Year 0.82 3 Year 0.71
Over 1 Month
20.10% down
Over 1 Year
-34.39% down
Over 3 Months
15.26% down
Over 3 Years
12.81% down
Over 6 Months
-1.16% down
Over 5 Years
0.00% down

CONCORD BIOTECH LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
03 Sep 2025 10.7 Final 03 Sep 2025 Equity shares
21 Jun 2024 8.75 Final 22 Jun 2024 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
03 Sep 2025 10.7 Final 03 Sep 2025 Equity shares
21 Jun 2024 8.75 Final 22 Jun 2024 Equity shares

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Concord Biotech Ltd?

Answer Field

Concord Biotech Ltd share price is for NSE ₹ 1,353.80 & for BSE ₹ 1,351.90 as on Jun 12 2026 03:30 PM.

What is the Market Cap of Concord Biotech Ltd Share?

Answer Field

The market cap of Concord Biotech Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 12 2026 03:30 PM.

What is the 52 Week High and Low of Concord Biotech Ltd?

Answer Field

The 52 Week High and Low of Concord Biotech Ltd for NSE is ₹ 2,146.00 and ₹ 987.00 and for BSE is ₹ 2,143.95 and ₹ 987.05.

What is 1 year return for Concord Biotech Ltd?

Answer Field

The 1 year returns on the stock has been -34.39%.

What is the P/E Ratio of Concord Biotech Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM the price-to-earnings (PE) ratio for Concord Biotech Ltd share is 53.79.

What is the PB ratio of Concord Biotech Ltd Share?

Answer Field

As on Jun 12 2026 03:30 PM, the price-to-book (PB) ratio for Concord Biotech Ltd share is 193.06.

How to Buy Concord Biotech Ltd Share?

Answer Field

You can trade in Concord Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Concord Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Concord Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Concord Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|